16.03.21
12.03.21
10.03.21
We are pleased to share the following update from Cyclo Therapeutics entitled 'Cyclo Therapeutics Appoints Russ Belden as Acting Chief Commercial Officer'...
Read more09.03.21
We are pleased to share the latest update from Cyclo Therapeutics entitled: Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol® Cyclo™...
Read more04.03.21
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease, today announced that the last patient completed their last visit in the Phase 1/2 study evaluating Trappsol® Cyclo™...
Read more